Epstein DM, et al. - Researchers undertook a within-trial cost-utility analysis with a 1-year time horizon using data from the EVRA (Early Venous Reflux Ablation) trial to evaluate the costs and cost-efficacy of early vs delayed endovenous treatment of patients with venous leg ulcers. Observations indicated an 89% probability that early venous intervention is cost-effective at a threshold of £20 000(€22 546)/quality-adjusted life-year (QALY). This indicates that in patients with venous leg ulcers over 1 year, early treatment of superficial reflux is highly likely to be cost-effective.